Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells.

J Photochem Photobiol B

Central Laser Facility, Science & Technology Facilities Council, Rutherford Appleton Laboratory, Harwell Campus, Didcot, Oxfordshire OX11 0QX, UK. Electronic address:

Published: December 2020

The range of cellular functions the mechanistic target of rapamycin (mTOR) protein performs makes it an attractive drug target for cancer therapy. However, the cellular localisation and mode of action of second generation inhibitors of mTOR is poorly understood despite the level of attention there is in targeting the mTOR protein. We have therefore studied the properties of the pan-mTOR inhibitor AZD2014, an ideal candidate to study because it is naturally fluorescent, characterising its photochemical properties in solution phase (DMSO, PBS and BSA) and within living cells, where it localises within both the nucleus and the cytoplasm but with different excited state lifetimes of 4.8 (+/- 0.5) and 3.9 (+/- 0.4) ns respectively. We measure the uptake of the inhibitor AZD2014 (7 μM) in monolayer HEK293 cells occurring with a half-life of 1 min but observe complex behaviour for 3D spheroids with the core of the spheroid showing a slower uptake and a slow biphasic behaviour at longer times. From a cellular perspective using fluorescence lifetime imaging microscopy AZD2014 was found to interact directly with GFP-tagged mTORC1 proteins including the downstream target, S6K1. We observe light sensitive behaviour of the cells containing AZD2014 which leads to cell death, in both monolayer and spheroids cells, demonstrating the potential of AZD2014 to act as a possible photodynamic drug under both single photon and multiphoton excitation and discuss its use as a photosensitizer. We also briefly characterise another pan-mTOR inhibitor, INK128.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762844PMC
http://dx.doi.org/10.1016/j.jphotobiol.2020.112055DOI Listing

Publication Analysis

Top Keywords

pan-mtor inhibitor
12
inhibitor azd2014
12
properties pan-mtor
8
mtor protein
8
azd2014
6
cells
5
directly imaging
4
imaging localisation
4
localisation photosensitization
4
photosensitization properties
4

Similar Publications

Article Synopsis
  • Hepatocellular carcinoma (HCC) is a deadly primary liver cancer with limited treatment options for advanced stages, necessitating new therapeutic strategies.
  • The study found that eukaryotic initiation factor 4A1 (eIF4A1) is significantly upregulated in HCC tissues and is linked to poorer patient prognosis.
  • Blocking eIF4A1 with specific inhibitors led to decreased tumor cell growth and increased cell death, with enhanced effects observed when combined with the mTOR inhibitor Rapalink-1, suggesting a promising avenue for HCC treatment.
View Article and Find Full Text PDF

Pan-mTOR inhibitors sensitize the senolytic activity of navitoclax via mTORC2 inhibition-mediated apoptotic signaling.

Biochem Pharmacol

June 2022

The Lab of Aging Research, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 1 Keyuan 4 Road, Gaopeng Avenue, Chengdu, China. Electronic address:

Compounds with senolysis activity are discovered in recent years, featuring by their capacity to specifically eliminate senescent cells in vitro or in vivo. These compounds, referring to as Senolytics, provide a new method for aging counteraction and probably for geriatric disease amelioration. However, their clinical application is unpractical still, mainly because of the safety issue.

View Article and Find Full Text PDF

Senolytics are basically anti-cancer drugs, repurposed to kill senescent cells selectively. It is even more difficult to selectively kill senescent cells than to kill cancer cells. Based on lessons of cancer therapy, here I suggest how to exploit oncogene-addiction and to combine drugs to achieve selectivity.

View Article and Find Full Text PDF

The clinical benefits of pan-mTOR active-site inhibitors are limited by toxicity and relief of feedback inhibition of receptor expression. To address these limitations, we designed a series of compounds that selectively inhibit mTORC1 and not mTORC2. These 'bi-steric inhibitors' comprise a rapamycin-like core moiety covalently linked to an mTOR active-site inhibitor.

View Article and Find Full Text PDF

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.

Gut

September 2021

Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA

Objective: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by Food and Drug Administration (FDA) for HCC patients. We evaluated the therapeutic efficacy of cabozantinib, either alone or in combination, in vitro and in vivo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!